organization · Reporting owner
Nutritional Health LTP Fund General Partner LLC
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evelo Biosciences, Inc.EVLO · Entity 108468 | 10% owner | July 11, 2023 | July 13, 2023 |
| Generate Biomedicines, Inc.GENB · Entity 1553 | 10% owner | February 26, 2026 | March 02, 2026 |
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | 10% owner | February 08, 2021 | February 10, 2021 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | 10% owner | August 03, 2021 | August 05, 2021 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | 10% owner | July 05, 2022 | July 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evelo Biosciences, Inc.
Report date July 11, 2023 · Filed July 13, 2023
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Nutritional Health LTP Fund, L.P., Flagship Pioneering, LLC, Flagship Pioneering Fund VII General Partner LLC, Flagship Pioneering Fund VII, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV, L.P. | 1,461,795 |
Reported balance
After 2023-07-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-07-11 · Purchase · Acquired 1,082,251 · Balance 1,461,795 F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health LTP Fund, L.P. | 1,493,241 |
Reported balance
After 2023-07-11 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-07-11 · Purchase · Acquired 1,082,251 · Balance 1,493,241 F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F3: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Nutritional LTP GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 3,931,685 |
Reported balance
After 2023-07-11 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2023-07-11 · Purchase · Acquired 3,246,753 · Balance 3,931,685 F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F4: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV-Rx, L.P. | 94,371 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 94,371 F5: Shares held by Flagship Ventures Fund IV-Rx, L.P ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Opportunities Fund I, L.P. | 274,766 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 274,766 F6: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs IV LLC | 34,219 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 34,219 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is the manager of VentureLabs IV. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs V LLC | 132,282 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 132,282 F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund V, L.P. | 210,064 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 210,064 F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship V VentureLabs Rx Fund, L.P. | 80,494 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 80,494 F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health Side Fund, L.P. | 39,798 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 39,798 F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health Disruptive Innovation Fund, L.P. | 179,909 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 179,909 F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share.
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Nutritional LTP GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F4: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: Shares held by Flagship Ventures Fund IV-Rx, L.P ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is the manager of VentureLabs IV. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Generate Biomedicines, Inc.
Report date February 26, 2026 · Filed March 02, 2026
Jointly reported with Afeyan Noubar, Flagship Pioneering, LLC, Flagship VentureLabs VI Manager LLC, Flagship Pioneering Fund VI General Partner LLC, Flagship Pioneering Fund VII General Partner LLC, Flagship Pioneering Special Opportunities Fund II General Partner LLC, FPN General Partner LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VI, L.P. | 12,723,940 |
Reported balance
After 2026-03-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-03-02 · Conversion · Acquired 12,723,940 · Balance 12,723,940 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 15,264,724 |
Last balance in matching sequence
After 2026-03-02 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2026-03-02 · Conversion · Acquired 13,702,224 · Balance 13,702,224 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Row 6 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 15,264,724 F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health LTP Fund, L.P. | 987,491 |
Reported balance
After 2026-03-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-03-02 · Conversion · Acquired 987,491 · Balance 987,491 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 2,777,752 |
Reported balance
After 2026-03-02 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-03-02 · Conversion · Acquired 2,777,752 · Balance 2,777,752 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy FPN II, L.P. | 4,340,252 |
Last balance in matching sequence
After 2026-03-02 transaction · row 7
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 5 · 2026-03-02 · Conversion · Acquired 2,777,752 · Balance 2,777,752 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Row 7 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 4,340,252 F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Pioneering Medicines 02, LLC | 1,562,500 |
Reported balance
After 2026-03-02 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 1,562,500 F7: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25 | Direct | 29,561 |
Reported balance
After 2026-02-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F9: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VI, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-02 · Conversion · Disposed 18,483,785 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VII, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-02 · Conversion · Disposed 17,016,215 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Nutritional Health LTP Fund, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-02 · Conversion · Disposed 1,500,000 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VI, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-02 · Conversion · Disposed 843,881 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VII, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-03-02 · Conversion · Disposed 1,265,822 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-03-02 · Conversion · Disposed 2,953,586 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy FPN II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-03-02 · Conversion · Disposed 2,109,704 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VII, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-03-02 · Conversion · Disposed 2,531,644 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2026-03-02 · Conversion · Disposed 1,265,822 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy FPN II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2026-03-02 · Conversion · Disposed 2,109,704 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs VI, LLC | 25,016,458 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 25,016,458 F8: Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date.
F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F7: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F8: Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F9: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
Kaleido Biosciences, Inc.
Report date February 08, 2021 · Filed February 10, 2021
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Flagship Ventures Opportunities Fund I, L.P., Nutritional Health LTP Fund, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,685,444 |
Reported balance
After 2021-02-08 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-02-08 · Purchase · Acquired 71,666 · Balance 1,685,444 F1: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,982,639 |
Reported balance
After 2021-02-08 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-02-08 · Purchase · Acquired 71,667 · Balance 2,982,639 F3: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 738,333 |
Reported balance
After 2021-02-08 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-02-08 · Purchase · Acquired 71,667 · Balance 738,333 F5: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering. F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 42,865 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 42,865 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,500,000 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,500,000 F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,560,096 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,560,096 F9: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 639,360 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 639,360 F10: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,560,523 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 6,560,523 F11: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 216,451 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 216,451 F12: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,649,999 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 1,649,999 F13: Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering.
F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering.
F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F10: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F11: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F12: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F13: Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Omega Therapeutics, Inc.
Report date August 03, 2021 · Filed August 05, 2021
Jointly reported with Flagship Pioneering, LLC, Flagship Pioneering Fund VI General Partner LLC, Flagship Pioneering Fund VI, L.P., Flagship Pioneering Special Opportunities Fund II, L.P., Flagship Pioneering Special Opportunities Fund II General Partner LLC, Nutritional Health LTP Fund, L.P., FPN General Partner LLC, FPN, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 1,088,470 |
Reported balance
After 2021-08-03 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-08-03 · Conversion · Acquired 1,088,470 · Balance 1,088,470 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F2: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 5,896,386 |
Reported balance
After 2021-08-03 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-08-03 · Conversion · Acquired 5,896,386 · Balance 5,896,386 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F3: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 8,396,825 |
Reported balance
After 2021-08-03 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-08-03 · Conversion · Acquired 8,396,825 · Balance 8,396,825 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 8,617,413 |
Reported balance
After 2021-08-03 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2021-08-03 · Purchase · Acquired 220,588 · Balance 8,617,413 F4: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 970,588 |
Reported balance
After 2021-08-03 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2021-08-03 · Conversion · Acquired 970,588 · Balance 970,588 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F5: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 4,852,943 |
Reported balance
After 2021-08-03 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2021-08-03 · Conversion · Acquired 4,852,943 · Balance 4,852,943 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F6: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 5,514,707 |
Reported balance
After 2021-08-03 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2021-08-03 · Purchase · Acquired 661,764 · Balance 5,514,707 F6: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 1,323,529 |
Reported balance
After 2021-08-03 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2021-08-03 · Conversion · Acquired 1,323,529 · Balance 1,323,529 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F7: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 1,617,646 |
Reported balance
After 2021-08-03 transaction · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · 2021-08-03 · Purchase · Acquired 294,117 · Balance 1,617,646 F7: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 2,197,059 |
Reported balance
Holding disclosure · report date 2021-08-03 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 2,197,059 F8: Represents shares held directly by Flagship VentureLabs V, LLC ("VentureLabs V"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-08-03 · Conversion · Disposed 4,112,000 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F2: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-08-03 · Conversion · Disposed 22,275,232 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F3: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-08-03 · Conversion · Disposed 27,388,000 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-08-03 · Conversion · Disposed 3,000,000 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F5: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2021-08-03 · Conversion · Disposed 2,666,667 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2021-08-03 · Conversion · Disposed 666,667 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F5: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2021-08-03 · Conversion · Disposed 13,333,333 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F6: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2021-08-03 · Conversion · Disposed 3,333,333 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F7: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2021-08-03 · Conversion · Disposed 1,666,667 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2021-08-03 · Conversion · Disposed 5,000,000 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F6: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2021-08-03 · Conversion · Disposed 1,666,666 · Balance 0 F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F7: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering.
F2: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx").
F3: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V").
F4: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI").
F5: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP").
F6: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II")
F7: Represents shares held directly by FPN, L.P. ("FPN Fund").
F8: Represents shares held directly by Flagship VentureLabs V, LLC ("VentureLabs V").
F9: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP").
F10: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners").
F11: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.
Seres Therapeutics, Inc.
Report date July 05, 2022 · Filed July 07, 2022
Jointly reported with Nutritional Health LTP Fund, L.P., Flagship Pioneering, LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health LTP Fund, L.P. | 5,875,711 |
Reported balance
After 2022-07-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-07-05 · Purchase · Acquired 2,912,748 · Balance 5,875,711 F1: On July 5, 2022, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 2,912,748 shares and 5,825,495 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share. F2: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 5,825,495 |
Reported balance
After 2022-07-05 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-07-05 · Purchase · Acquired 5,825,495 · Balance 5,825,495 F1: On July 5, 2022, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 2,912,748 shares and 5,825,495 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share. F3: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV, L.P. | 4,434,600 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,434,600 F4: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV-Rx, L.P. | 1,283,282 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,283,282 F5: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VI, L.P. | 2,962,963 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,962,963 F6: Shares held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Dr. Afeyan is the CEO, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs IV LLC | 2,734,994 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,734,994 F7: Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Each of the reporting persons except VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Noubar B. Afeyan, Ph.D. | 376,018 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 376,018 F8: Shares held by Dr. Afeyan. Each of the reporting persons except for Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Includes 12,853 shares held through a trust for the benefit of Dr. Afeyan's children. Dr. Afeyan disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 5, 2022, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 2,912,748 shares and 5,825,495 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share.
F2: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F4: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6: Shares held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering is the manager of Flagship Fund VI GP. Dr. Afeyan is the CEO, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VI disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Each of the reporting persons except VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Dr. Afeyan. Each of the reporting persons except for Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Includes 12,853 shares held through a trust for the benefit of Dr. Afeyan's children. Dr. Afeyan disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares for Section 16 or any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries C Preferred Stock · Derivative | 2,109,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 20 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,388,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries C Preferred Stock · Derivative | 1,265,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 19 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 833,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5 · ownership.nature: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries C Preferred Stock · Derivative | 2,531,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 18 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,666,651 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 2,109,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 17 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,388,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 2,953,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 16 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,944,427 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5 · ownership.nature: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 1,265,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 15 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 833,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 843,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 14 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 555,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2 · ownership.nature: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries A Preferred Stock · Derivative | 1,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 13 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 0 Underlying: Common Stock · 987,491 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4 · ownership.nature: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries A Preferred Stock · Derivative | 17,016,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 12 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 11,202,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries A Preferred Stock · Derivative | 18,483,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 11 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 12,168,390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2 · ownership.nature: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · nonDerivative · entry 8 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pioneering Medicines 02, LLC Disclosed balance after: 1,562,500 F7 · ownership.nature: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · nonDerivative · entry 7 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 4,340,252 F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · nonDerivative · entry 6 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 15,264,724 F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 2,777,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · nonDerivative · entry 5 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 2,777,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 2,777,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · nonDerivative · entry 4 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 2,777,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5 · ownership.nature: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 987,491 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · nonDerivative · entry 3 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 987,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4 · ownership.nature: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 13,702,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · nonDerivative · entry 2 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 13,702,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 12,723,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · nonDerivative · entry 1 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VI, L.P. Disclosed balance after: 12,723,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2 · ownership.nature: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 17:52 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | GrantStock Option (Right to Buy) · Derivative | 29,561 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085888 · ownership.xml · derivative · entry 10 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship Pioneering, LLC · CIK 0001400240 · 10% owner Flagship VentureLabs VI Manager LLC · CIK 0001860060 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,561 Underlying: Common Stock · 29,561 shares Expires 2036-02-25 F9 · derivative.exercise_date: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:15 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 3,246,753 | $2.31 | $7,499,999.43 |
DisclosureSEC source: 0000950170-23-032871 · ownership.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 3,931,685 F1 · kind: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F4 · ownership.nature: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:15 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,082,251 | $2.31 | $2,499,999.81 |
DisclosureSEC source: 0000950170-23-032871 · ownership.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 1,493,241 F1 · kind: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F3 · ownership.nature: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Nutritional LTP GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:15 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,082,251 | $2.31 | $2,499,999.81 |
DisclosureSEC source: 0000950170-23-032871 · ownership.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Ventures Fund IV, L.P. Disclosed balance after: 1,461,795 F1 · kind: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:00 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | PurchaseCommon Stock | 5,825,495 | $3.15 | $18,350,309.25 |
DisclosureSEC source: 0000899243-22-025721 · doc4.xml · nonDerivative · entry 2 Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 5,825,495 F1 · kind: On July 5, 2022, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 2,912,748 shares and 5,825,495 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share. F3 · ownership.nature: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:00 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | PurchaseCommon Stock | 2,912,748 | $3.15 | $9,175,156.20 |
DisclosureSEC source: 0000899243-22-025721 · doc4.xml · nonDerivative · entry 1 Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 5,875,711 F1 · kind: On July 5, 2022, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 2,912,748 shares and 5,825,495 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share. F2 · ownership.nature: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 19:00 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 13,698,630 | $1.46 | $19,999,999.80 |
DisclosureSEC source: 0000899243-22-020533 · doc4.xml · nonDerivative · entry 5 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 13,698,630 F1 · kind: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F6 · ownership.nature: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 19:00 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 6,849,315 | $1.46 | $9,999,999.90 |
DisclosureSEC source: 0000899243-22-020533 · doc4.xml · nonDerivative · entry 4 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 8,219,791 F1 · kind: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F5 · ownership.nature: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 19:00 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,369,863 | $1.46 | $1,999,999.98 |
DisclosureSEC source: 0000899243-22-020533 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Opportunities Fund I, L.P. Disclosed balance after: 5,495,324 F1 · kind: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F4 · ownership.nature: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 19:00 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,095,890 | $1.46 | $1,599,999.40 |
DisclosureSEC source: 0000899243-22-020533 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 1,887,419 F1 · kind: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F3 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 19:00 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 4,383,561 | $1.46 | $6,399,999.06 |
DisclosureSEC source: 0000899243-22-020533 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. Disclosed balance after: 7,590,873 F1 · kind: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,666,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 21 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 441,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F7 · ownership.nature: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries C Convertible Preferred Stock · Derivative | 5,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 20 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,323,530 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,666,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 19 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 441,176 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,333,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 18 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 882,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F7 · ownership.nature: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries B Convertible Preferred Stock · Derivative | 13,333,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 17 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 3,529,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries B Convertible Preferred Stock · Derivative | 666,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 16 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 176,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F5 · ownership.nature: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries B Convertible Preferred Stock · Derivative | 2,666,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 15 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 705,882 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries A Convertible Preferred Stock · Derivative | 3,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 14 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 794,118 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F5 · ownership.nature: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries A Convertible Preferred Stock · Derivative | 27,388,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 13 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 7,249,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries A Convertible Preferred Stock · Derivative | 22,275,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 12 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 5,896,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F3 · ownership.nature: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionSeries A Convertible Preferred Stock · Derivative | 4,112,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · derivative · entry 11 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,088,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | PurchaseCommon Stock | 294,117 | $17.00 | $4,999,989.00 |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 9 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,617,646 F7 · ownership.nature: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 1,323,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 8 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,323,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F7 · ownership.nature: Represents shares held directly by FPN, L.P. ("FPN Fund"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | PurchaseCommon Stock | 661,764 | $17.00 | $11,249,988.00 |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 7 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,514,707 F6 · ownership.nature: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 4,852,943 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 6 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 4,852,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Represents shares held directly by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II") F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 970,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 5 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 970,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F5 · ownership.nature: Represents shares held directly by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | PurchaseCommon Stock | 220,588 | $17.00 | $3,749,996.00 |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 4 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,617,413 F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 8,396,825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 3 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 8,396,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 5,896,386 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 2 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,896,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F3 · ownership.nature: Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 17:41 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | ConversionCommon Stock | 1,088,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031796 · doc4.xml · nonDerivative · entry 1 Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VI General Partner LLC · CIK 0001724957 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner FPN General Partner LLC · CIK 0001860059 · 10% owner FPN, L.P. · CIK 0001860062 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,088,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's preferred stock have no expiration date and are convertible at the holder's election into Issuer's common stock at a conversion ratio of 1-to-0.264706. The preferred stock will automatically convert into shares of the Issuer's common stock, for no additional consideration, upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx"). F9 · ownership.nature: Flagship Fund V is a member of VentureLabs V. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP"). The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The General Partner of Flagship Opportunities Fund II is Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP"). F10 · ownership.nature: (continued from above) The general partner of FPN Fund is FPN General Partner LLC ("FPN GP"). The manager of Flagship Pioneering VI GP, Flagship Opportunities Fund II GP, and FPN GP is Flagship Pioneering. The general partner of Nutritional LTP is Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP" and, together with VentureLabs V Manager, Flagship Pioneering, Flagship V GP, Flagship Pioneering VI GP, Flagship Opportunities Fund II GP and FPN GP, the "Flagship General Partners"). F11 · ownership.nature: (continued from above) Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole director of Flagship Pioneering and may be deemed to have beneficial ownership of all the shares held by VentureLabs V, Flagship Pioneering VI, Flagship Opportunities Fund II and FPN Fund. In addition, Dr. Afeyan serves as the sole manager of Flagship V GP and is the sole member and manager of Nutritional LTP GP and may be deemed to have beneficial ownership of all the shares held by Flagship Fund V, Flagship Fund V Rx and Nutritional LTP. None of the Flagship General Partners nor Dr. Afeyan directly own any of the shares held by the Reporting Persons, and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Read SEC document |
| May 17, 2021 Filed May 19, 2021 19:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | OtherCommon Stock | 295,171 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-020015 · doc4.xml · nonDerivative · entry 1 Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,962,963 F1 · kind: On May 17, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") distributed to its limited partner(s), pro rata and without consideration, 295,171 shares of the Issuer's common stock. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Noubar B. Afeyan Ph.D. is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.